A lack of evidence is behind the NHS' decision to withhold a breakthrough prostate cancer drug from patients who have already been treated using another new generation drug, Nice said.
A spokeswoman for Nice said the committee were unable to "draw any conclusions" about what would happen if "milestone" enzalutamide was used by prostate cancer sufferers who had also taken abiraterone.
In the trial data provided by the manufacturer of enzalutamide none of the patients had received previous treatment with abiraterone, therefore the committee was not able to draw any conclusions about the effectiveness of enzalutamide after previous abiraterone treatment, and this is reflected in the recommendations.
We would welcome any additional data the manufacturer of enzalutamide can provide.
More top news
Climate change is a pressing issue for Tonga, but has it had the attention it deserves at the Commonwealth summit?
With temperatures peaking at 29C today, it is the hottest April day for nearly 70 years.
Russian trolls are behind a disinformation campaign about chemical weapons attacks in Syria and Salisbury, a government source has said.